Novartis to buy The Medicines Company for $9.7 billion

Business News
This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

Swiss pharmaceutical company Novartis has reached a deal to buy cholesterol drugmaker The Medicines Co. for $9.7 billion.

Novartis will pay $85 per share for the New Jersey biotech company, a sharp increase over The Medicine Co.’s Friday closing price of $68.55 per share. The deal is worth $9.7 billion, including outstanding stock options and convertible debt.

The Medicines Co. is in late-stage studies of a drug, inclisiran, meant to lower cholesterol.

Novartis has a pattern of acquiring other companies in recent years to expand its portfolio of drugs.

“We’re hoping to reimagine treatment of the leading global cause of death. This could be a strong step forward in Novartis’ transformation into a focused medicines company,” Novartis CEO Vas Narasimhan tweeted Sunday.

The Medicines Co. focuses on researching treatments for cardiovascular disease, specifically looking at ways to lower so-called bad cholesterol.

The deal is expected to close early next year.

Copyright 2020 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

COVID-19 IN CENTRAL ILLINOIS

National Unemployment Tracker

Trending Stories

Latest Local News

More Local News